





INV. No. Patient Name Age/Gen Referred By

QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female

Dr. Self

Source BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM

Report Generated 26/08/2024 12:24 PM



Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range	
GLUCOSE FASTING (FBS Plasma Glucose(F) Method (GOD-POD Method)	90.6	mg/dL	65 - 110	

Comments:

Fasting Blood Sugar/Glucose test a blood sample will be taken after an overnight fast. A fasting blood sugar level of less than 100mg/dL is normal. A fasting blood sugar level from 100 to 125 mg/dL is considered prediabetes. If it's 126 mg/dL or higher on two separate tests, you have diabetes.

GLYCOSYLATED HAEMOGLOBIN

Whole blood HbA1c Method (HPLC)		5.2	%	Non diabetic level(< 6.0) Goal(< 7.0)
Whole blood eAG (Estim	nated	103	mg/dl	-
AverageGlucose Level)				
Method (CALCULATION)				

Note:

The Parameter indicates control over the last 90 Days

In the Blood, glucose adheres to haemoglobin (Hb) and make Glycosylated haemoglobin/HbA₁C, which provides a clue about the average blood glucose level over the last 8-12 weeks and it is an indicator for chronic glycaemic control along with effects of drug, diet and exercise.

In normal individuals, 90% is the adult haemoglobin fraction and the rest 8% is formed by HbA. Reduction of HbA_1C value reduces diabetic and cardiological related morbidity and mortality.

The short life span of RBC in haemoglobinopathy and chemically modified derivatives of haemoglobin (carbamylated Hb in renal failure and acetylated Hb, who are taking aspirin) can affect the results. Iron deficiency anaemia, liver disease, opiate addiction may interfere the test value.

HPLC, ion exchange chromatography is the ideal method for HbA_1C estimation. The target goal is <7%. Besides HbA_1C serum fructosamine can be measured.

American diabetes association guideline

Reference range

Non diabetic adult > 18 years : < 5.7%Pediabetes : 5.7% - 6.4%Diagnosing diabetes : > 6.5%

Lipid Profile

Serum Triglyceride 70.5 mg/dL < 150

Method (Enzymatic,end point)

Report ID:- 26951 | Page 1/4







INV. No. Patient Name Age/Gen Referred By QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female Dr. Self

Source BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM 26/08/2024 11:14 AM 26/08/2024 11:14 AM

Report Generated 26/08/2024 12:24 PM

Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range
Serum Cholesterol Method (Oxidase, Esterase, Peroxidase)	139.7	mg/dL	125 - 200
Serum HDL-Chol Method (PTA/MgC12, Reflectance photometry)	34.7	mg/dL	30 - 65
Serum LDL-Chol Method (Direct Homogeneous, Spectrophotometry)	90.9	mg/dL	85 - 150
Serum VLDL-Chol	14	mg/dL	5 - 40
Serum LDL/HDL Cholester ol Ratio Method (Calculated)	2.62		1.5 - 3.5
Serum Cholesterol/ HDL Ratio	4.03		Low Risk(0 - 3) High Risk(5 - 10)

Interpretation:

NATIONAL LIPID	TOTAL	CHOLESTEROL	inTRIGLYCERIDE	LDL	NON	HDL
ASSOCIATION	mg/dL		in mg/dL	CHOLESTEROL	CHOLESTEROL	
RECOMMENDATIONS				in mg/dL	in mg/dL	
(NLA-2014)						
Optimal	<200		<150	<100	<130	
Above Optimal		-	-	100- 129	130 - 159	
Borderline High	200-23	9	150-199	130-159	160 - 189	
High	>=240		200-499	160-189	190 - 219	
Very High		-	>=500	>=190	>=220	

Note:

- 1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
- 2. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk factors.
- 3. Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense LDL particles, a pattern known as atherogenic dyslipidemia.
- 4. Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL remnants, Chylomicron remnants & Lp(a).
- LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary treatment

Report ID:- 26951 | Page 2/4





Certificate No.

INV. No. Patient Name Age/Gen Referred By QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female

Dr. Self

Source BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM Papert Congreted 26/08/2024 12:24 PM

Report Generated 26/08/2024 12:24 PM

Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range	

target

- 6. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved.
- 7. Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

Liver Function Test Serum Bilirubin (Total) Method (By Diphylline, Diazonium		0.58	mg/dL	0.2 - 1.3
Serum Bilirubin (Direct) Method (Diphylline, Diazonium Sa		0.19	mg/dL	0.1 - 0.4
Serum Bilirubin (Indirect Method (Calculated)	t)	0.39	mg/dL	0.2 - 1.1
Serum SGOT Method (IFCC)		20.6	U/L	17 - 59
Serum SGPT Method (IFCC)		28.1	U/L	21 - 72
Alkaline phosphatase (A	ALP)	58.7	U/L	Adult (38 - 126)
Serum Total Protein Method (Biuret Method)		6.8	g/dL	Adult(6.2 - 8.2) Children(5.6 - 8.4)
Serum Albumin Method (BCG)		4.2	gm/dL	Newborn Children(2.4 - 4.8) Adult(3.5 - 5.0)
Serum Globulin Method (Calculated)		2.60	g/dL	Adult(2.3 - 3.6)
Serum A/G Ratio Method (BCG)		1.62		1.0 - 2.3

Note

- 1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
- 2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of advanced liver fibrosis.
- 3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.

Report ID:- 26951 | Page 3/4





Certificate No.
PESHCO-2022-6684

INV. No. Patient Name Age/Gen Referred By

Source

QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female Dr. Self

BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM

Report Generated 26/08/2024 12:24 PM

Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range	

4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

Kidney Function Tes Serum Urea Method (GLDH,Kinetic Assay)	st (KFT)	20.4	mg/dL	Adult (17 - 4 New Born (8 Infant (10.8	3.4 - 25.8)
Serum Creatinine Method (Modified Jaffe, Kinetic)		0.85	mg/dL	Female: (0.7 Neonate : (0	72-1.18) 0.26 - 1.01)
Serum Uric Acid		2.0	ma/dl	yrs} : (0.15- Children { 3 yrs} : (0.24	yrs - less than 15
Method (uricase-Colorimetric)		3.8	mg/dL	3.5 - 8.5	
Serum Sodium Method (By Indirect ISE)		137.4	mmol/L	136 - 145	
Serum Potassium Method (By Indirect ISE)		3.82	mmol/L	3.5 - 5.1	
Serum Chloride Method (By Ion-selective Electrode	e)	100.4	mmol/L	98 - 107	

~~~~~ End of report ~~~~~

Report ID:- 26951 | Page 4/4





Certificate No.

INV. No. Patient Name Age/Gen Referred By

Source

QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female

Dr. Self

BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM Report Generated 26/08/2024 12:28 PM

### **Report Of Immunology Examination**

| Result | Unit(s)      | Reference Range                                                                                                                                                  |
|--------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |              |                                                                                                                                                                  |
| 0.98   | ng/mL        | (0.8 - 2.0)<br>11-15 Years ( 0.83 - 2.13 )<br>1-10 Years ( 0.94 - 2.69 )<br>1-12 Months ( 1.05 - 2.45 )<br>1-7 Days ( 0.36 - 3.16 )<br>1-4 Weeks ( 1.05 - 3.45 ) |
| 8.46   | μg/dL        | (5.1 - 14.1)<br>1-12 Months ( 5.9 - 16 )<br>1-7 Days ( 11 - 22 )                                                                                                 |
| 1.64   | μlU/mL       | 1-4 Weeks ( 8.2 - 17 )<br>1-10 Years ( 6.4 - 15 )<br>11-15 Years ( 5.5 - 12 )<br>Up to 1 Week (0.7-11.0)                                                         |
|        |              | 1 week-4 week (0.7- 11.0)<br>1-12 Months (0.7- 8.4)<br>1-19 Years (0.6-4.9)                                                                                      |
|        |              | 19 Years Above (0.5-5.5)<br>1st Trimester (0.6 - 3.4)<br>2nd Trimester (0.37 - 3.6) 3rd<br>Trimester(0.38 - 4.04)                                                |
|        | 0.98<br>8.46 | 0.98 ng/mL<br>8.46 μg/dL                                                                                                                                         |

Mild to moderate degree of elevation normal T3&T4 levels indicates impaired thyroid hormone reserves and indicates subclinical hypothyroidism.

Mild to moderate decrease with normal T3 & T4 indicates subclinical hyperthyroidism.

TSH measurement is used for screening & diagnosis of Euthyroidism, hypothyroidism & hyperthyroidism. Suppressed TSH ( $< 0.01 \mu$  IU/ml) suggests diagnosis of hyperthyroidism.

Elevated concentration of TSH (>7 μ IU/ml) suggest diagnosis of hypothyroidism.

Please correlate clinically.

~~~~~ End of report ~~~~~

Report ID:- 26957 | Page 1/1





Certificate No.

INV. No. Patient Name Age/Gen Referred By

QLSR-INV-H-06804/(2024-2025)(6766) **Mrs. REETA LACKRA**

41 Years | Female

Dr. Self

Source BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM Report Generated 26/08/2024 03:26 PM

Report Of Haematology Examination

| Investigation | Result | Unit(s) | Reference Range |
|------------------------------|--------------|---------|-----------------|
| ERYTHROCYTE SEDIMEN | ITATION RATE | | |
| ESR | 24 | mm | < 20 |
| Method (Westergren & Manual) | | | |

Note

- 1. C-Reactive Protein (CRP) is the recommended test in acute inflammatory conditions.
- 2. Test conducted on EDTA whole blood at 37°C.
- 3. ESR readings are auto- corrected with respect to Hematocrit (PCV) values

| COMPLETE BLOOD C | OUNT | | | |
|--|------------|-------------------|--------------|---|
| Haemoglobin (Hb)% | | 9.3 | gm% | Adult Men (13 - 18) |
| Method (By Sahlis Method) | | | | Adult Women (11.5 - 16.5) |
| | | | | Children (11 - 13) |
| | | | | Children (1-6) : (12 - 14) |
| | | | | Children (6-12) : (12 - 14) |
| PCV | | 31.2 | % | 35 - 45 |
| Total Platelets Count (PC | • | 1.9 | Lacs Per cmm | _ |
| Total RBC (Red Cell Cou | nt) | 4.8 | mill./uL | Women (4.2 - 5.4) |
| | | | | Male (4.7 - 6.1) |
| | - \ | | | Children (4.6 - 4.8) |
| Total Leucocyte Count (Method (Flow Cytometry) | ILC) | 7,500 | Per cmm | Adult :- (4,000 - 11,000) |
| Method (How Cytometry) | | | | New Born (10,000 - 26,000) |
| | | | | (1-4) Years : (6,000 - 18,000) |
| | | | | (5-7) Years : (5,000 - 15,000)
(8-12) Years : (4,500 - 12,500) |
| MCV | | 64.0 | fl | 76 - 96 |
| MCH | | 19.1 | pg | 22 - 32 |
| MCHC | | 29.7 | g/dL | 30 - 35 |
| Differential count of I | _eucocv | | 9, | |
| Neutrophils | |
63 | % | 40 - 70 |
| Lymphocytes | | 33 | % | 15 - 40 |
| Monocytes | | 00 | % | 00 - 6 |
| Eosinophils | | 04 | % | 0.5 - 7 |
| Basophils | | 00 | % | 00 - 01 |

Comment:

CBC is a powerful diagnostic tool in various hematological and non-hematological conditions. It can be

Report ID:- 27065 | Page 1/2



Dr. R. Verma



INV. No. QLSR-INV-H-06804/(2024-2025)(6766)

Patient Name Mrs. REETA LACKRA Age/Gen 41 Years | Female

Referred By **Dr. Self**

Source BERLIN DIAG CGHS - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM Report Congreted 26/08/2024 03:26 PM

Report Generated 26/08/2024 03:26 PM

Report Of Haematology Examination

Investigation Result Unit(s) Reference Range

used to diagnose various conditions like anemia, hemoglobinopathies, infections. leukemia, nutritional deficiencies, parasitemias, etc. For microcytic indices, a Mentzer index of less than 13 suggests that the patient may have thalassemia trait, and an index of more than 13 suggests that the patient may have iron deficiency.

Blood Grouping (A B O) and Rh Type

Whole blood Blood Group Whole blood Rh Type

"A" Positive

Note:

- 1. Both forward and rever<mark>se grouping performed.</mark>
- 2. Test conducted on EDTA whole blood.

~~~~~ End of report ~~~~~

Report ID:- 27065 | Page 2/2







INV. No. Patient Name Age/Gen Referred By

Source

QLSR-INV-H-06804/(2024-2025)(6766)

Mrs. REETA LACKRA 41 Years | Female

Dr. Self

BERLIN DIAG INS CORP - (4)

Patient ID 6804

Invoice Generated 26/08/2024 11:14 AM Sample Received 26/08/2024 11:14 AM Report Generated 06/09/2024 11:36 AM

### **Report Of Clini Patho Examination**

| Investigation                                   |        |            | Result                    | Unit(s)    | Reference Range |  |  |  |
|-------------------------------------------------|--------|------------|---------------------------|------------|-----------------|--|--|--|
|                                                 |        |            |                           |            |                 |  |  |  |
| Urine Routine and Microscopic Examination (R/M) |        |            |                           |            |                 |  |  |  |
| Physical Examination                            |        |            | C.                        |            | D I V II        |  |  |  |
| Colour                                          |        |            | Straw                     |            | Pale Yellow     |  |  |  |
| Urine Appearance                                |        |            | Transparent               |            |                 |  |  |  |
| Urine Deposit                                   |        |            | Absent                    |            |                 |  |  |  |
| Urine Specific Gravity                          |        |            | 1.025                     |            | 1.010 - 1.030   |  |  |  |
| Urine Reaction                                  |        |            | Acidic                    |            |                 |  |  |  |
| <b>Chemical Examination</b>                     | _      |            |                           |            |                 |  |  |  |
| Urine Glucose (Sugar)                           |        |            | Absent                    | gm%        |                 |  |  |  |
| Urine Protein (Albumin)                         |        |            | Absent                    |            |                 |  |  |  |
| Urine pH                                        |        |            | 6.0                       |            | 6.0             |  |  |  |
| Urine Ketone Body                               |        |            | Absent                    |            |                 |  |  |  |
| Urine Blood                                     |        |            | Negative                  |            |                 |  |  |  |
| Urine Phosphate (Amorp                          | hous d | eposits)   | Absent                    |            |                 |  |  |  |
| Urine Microscopic Exa                           | minat  | <u>ion</u> |                           |            |                 |  |  |  |
| Urine Red blood cells                           |        |            | Absent                    | /HPF       | 0-2             |  |  |  |
| Urine Pus Cells                                 |        |            | 1-2                       | /HPF       | 0-5             |  |  |  |
| Urine Epithelial cells                          |        |            | 2-4                       | /HPF       | 0-4             |  |  |  |
| Urine Bacteria                                  |        |            | Absent                    |            |                 |  |  |  |
| Urine Cast                                      |        |            | Absent                    | /HPF       |                 |  |  |  |
| Urine Crystals                                  |        |            | Absent                    | /HPF       |                 |  |  |  |
| Urine Yeast cells                               |        |            | Absent                    | •          |                 |  |  |  |
|                                                 |        |            | 7.1.000.1.0               |            |                 |  |  |  |
|                                                 |        | ~~~        | $\sim \sim \sim$ End of r | eport ~~~~ | ~               |  |  |  |
|                                                 |        |            | Liid Oi i                 | 2,000      |                 |  |  |  |
|                                                 |        |            |                           |            |                 |  |  |  |

Report ID:- 29367 | Page 1/1













| Patient Name | MRS. REETA LACKRA | Requested By   | MEDIWHEEL                     |
|--------------|-------------------|----------------|-------------------------------|
| MRN          | BER/2024/OPD24865 | Procedure Date | 24.08.2024                    |
| Age/Sex      | 41Y/FEMALE        | Hospital       | BERLIN DIAGNOSTICS & DAY CARE |

# **USG WHOLE ABDOMEN**

**Liver:** The liver is normal in size (11.5 cm) and outline. It shows a uniform echopattern. No obvious focal or diffuse pathology is seen. The intra and extra hepatic biliary passage are not dilated. The portal vein is normal in caliber at the porta hepatis.

Gall bladder: The gall bladder is normal in size, has normal wall thickness with no evidence of calculi.

CBD: The CBD is of normal caliber.

**Pancreas:** The pancreas is normal in size and echogenicity with distinct outline. No obvious focal lesion is seen.

Kidneys: Both kidneys were normal in position:

Right kidney Left kidney measures

9.1 cm

measures

9.3 cm

The renal cortical thickness and corticomedullary differentiation were adequate on both sides. No evidence of renal calculus or hydronephrosis seen on either side.

Spleen: The spleen is normal in size and echogenicity.

**Urinary Bladder:** The urinary bladder is normal in size. Its walls show a smooth outline. There is no evidence of any intraluminal or perivesical abnormality.

**Uterus :** The uterus is normal in size measuring 5.8 x 4.3 cm. Its outline is smooth. **An approx. 10 mm** size fibroid is seen in posterior uterine wall. No evidence of free fluid in the pouch of douglas. ET measures ~7.1 mm.

Right ovary measures :3.2 cm

Left ovary measures :3.0 cm

Both ovaries are normal in size and show uniform parenchymal echogenicity and smooth outline. There is no evidence of any mass lesion arising from or within either ovary.

No significant probe tenderness in RIF.

No evidence of pleural effusion on either side.

No evidence of ascites or lymphadenopathy seen.

**IMPRESSION: POSTERIOR WALL UTERINE FIBROID.** 

Please correlate clinically,

Dr. Ambuj Srivastav

M.D. Consultant Radiologist.